PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31067198-3	2019	We have also shown that injection of the specific and selective aminopeptidase A inhibitor, (3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid (EC33), by central route or its prodrug, RB150/firibastat, by oral route inhibited brain aminopeptidase A activity and blocked the formation of brain angiotensin III, normalizing blood pressure in hypertensive rats.	firibastat	180-185	glutamyl aminopeptidase	Rattus norvegicus	64-80
30882604-0	2019	A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.	firibastat	135-145	glutamyl aminopeptidase	Homo sapiens	107-123
30882604-1	2019	OBJECTIVES: We conducted a pilot multicenter double-blind randomized placebo-controlled crossover pharmacodynamic study to evaluate the blood pressure (BP) and the hormonal effects of firibastat, a first-in-class aminopeptidase A inhibitor prodrug, in patients with hypertension.	firibastat	184-194	glutamyl aminopeptidase	Homo sapiens	213-229
31014072-0	2019	Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.	firibastat	23-33	glutamyl aminopeptidase	Homo sapiens	58-74
31014072-16	2019	CONCLUSIONS: Our results demonstrate the efficacy of firibastat in lowering BP in a high-risk diverse population where monotherapy with angiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers may be less effective and support the strategy to further investigate firibastat in subjects with difficult-to-treat or potentially resistant hypertension.	firibastat	53-63	angiotensin II receptor type 1	Homo sapiens	182-212
31067198-3	2019	We have also shown that injection of the specific and selective aminopeptidase A inhibitor, (3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid (EC33), by central route or its prodrug, RB150/firibastat, by oral route inhibited brain aminopeptidase A activity and blocked the formation of brain angiotensin III, normalizing blood pressure in hypertensive rats.	firibastat	186-196	glutamyl aminopeptidase	Rattus norvegicus	64-80
28968260-0	2018	Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats.	firibastat	59-64	glutamyl aminopeptidase	Rattus norvegicus	83-99
31115779-4	2019	This identified brain APA as a potential therapeutic target for the treatment of hypertension, leading to the development of RB150/firibastat, an orally active prodrug of the specific and selective APA inhibitor, EC33.	firibastat	125-131	glutamyl aminopeptidase	Rattus norvegicus	22-25
31115779-4	2019	This identified brain APA as a potential therapeutic target for the treatment of hypertension, leading to the development of RB150/firibastat, an orally active prodrug of the specific and selective APA inhibitor, EC33.	firibastat	125-131	glutamyl aminopeptidase	Rattus norvegicus	198-201
31115779-4	2019	This identified brain APA as a potential therapeutic target for the treatment of hypertension, leading to the development of RB150/firibastat, an orally active prodrug of the specific and selective APA inhibitor, EC33.	firibastat	131-141	glutamyl aminopeptidase	Rattus norvegicus	22-25
31115779-4	2019	This identified brain APA as a potential therapeutic target for the treatment of hypertension, leading to the development of RB150/firibastat, an orally active prodrug of the specific and selective APA inhibitor, EC33.	firibastat	131-141	glutamyl aminopeptidase	Rattus norvegicus	198-201
31115779-5	2019	When given orally, RB150/firibastat crosses the gastrointestinal and blood-brain barriers, enters the brain, and generates two active molecules of EC33 which inhibit brain APA activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours in hypertensive rats.	firibastat	19-24	glutamyl aminopeptidase	Rattus norvegicus	172-175
31115779-5	2019	When given orally, RB150/firibastat crosses the gastrointestinal and blood-brain barriers, enters the brain, and generates two active molecules of EC33 which inhibit brain APA activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours in hypertensive rats.	firibastat	25-35	glutamyl aminopeptidase	Rattus norvegicus	172-175
30531435-1	2019	AIMS: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI).	firibastat	98-108	glutamyl aminopeptidase	Rattus norvegicus	65-81
30531435-1	2019	AIMS: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI).	firibastat	98-108	glutamyl aminopeptidase	Rattus norvegicus	83-86
30531435-1	2019	AIMS: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI).	firibastat	110-115	glutamyl aminopeptidase	Rattus norvegicus	65-81
30531435-1	2019	AIMS: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI).	firibastat	110-115	glutamyl aminopeptidase	Rattus norvegicus	83-86
30531435-7	2019	Both s.c. and oral firibastat inhibited brain APA and attenuated left ventricle dysfunction.	firibastat	19-29	glutamyl aminopeptidase	Rattus norvegicus	46-49
30599150-3	2019	We hypothesized that orally administered firibastat (previously named RB150), an APA inhibitor prodrug, would attenuate heart failure (HF) development after MI in mice, by blocking brain RAS hyperactivity.	firibastat	41-51	glutamyl aminopeptidase	Mus musculus	81-84
30599150-3	2019	We hypothesized that orally administered firibastat (previously named RB150), an APA inhibitor prodrug, would attenuate heart failure (HF) development after MI in mice, by blocking brain RAS hyperactivity.	firibastat	70-75	glutamyl aminopeptidase	Mus musculus	81-84
30599150-6	2019	Firibastat treatment normalized brain APA hyperactivity, with a return to the control values measured in sham group two weeks after MI.	firibastat	0-10	glutamyl aminopeptidase	Mus musculus	38-41
30599150-8	2019	Moreover, the mRNA levels of biomarkers of HF (Myh7, Bnp and Anf) were significantly lower following firibastat treatment.	firibastat	101-111	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	47-51
30599150-8	2019	Moreover, the mRNA levels of biomarkers of HF (Myh7, Bnp and Anf) were significantly lower following firibastat treatment.	firibastat	101-111	natriuretic peptide type B	Mus musculus	53-56
30599150-8	2019	Moreover, the mRNA levels of biomarkers of HF (Myh7, Bnp and Anf) were significantly lower following firibastat treatment.	firibastat	101-111	natriuretic peptide type A	Mus musculus	61-64
30599150-10	2019	Thus, chronic oral firibastat administration after MI in mice prevents cardiac dysfunction by normalizing brain APA hyperactivity, and attenuates cardiac hypertrophy and fibrosis.	firibastat	19-29	glutamyl aminopeptidase	Mus musculus	112-115
28968260-4	2018	We developed RB150, a prodrug of the specific and selective APA inhibitor, EC33.	firibastat	13-18	glutamyl aminopeptidase	Rattus norvegicus	60-63
28968260-9	2018	Chronic RB150 treatment also significantly decreased plasma arginine vasopressin levels and increased diuresis, which participate to BP decrease by reducing the size of fluid compartment.	firibastat	8-13	arginine vasopressin	Rattus norvegicus	69-80
22710644-5	2012	We demonstrated here the antihypertensive effects of RB150, a prodrug of the specific and selective aminopeptidase A inhibitor, EC33, in spontaneously hypertensive rats, a model of human essential hypertension.	firibastat	53-58	glutamyl aminopeptidase	Rattus norvegicus	100-116
25474003-6	2014	This justifies the development of potent systemically active APA inhibitors, such as RB150, as prototypes of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	85-90	glutamyl aminopeptidase	Homo sapiens	61-64
24697296-7	2014	This identified brain APA as a potential therapeutic target for the treatment of hypertension, which has led to the development of potent orally active APA inhibitors, such as RB150.	firibastat	176-181	glutamyl aminopeptidase	Rattus norvegicus	22-25
24697296-7	2014	This identified brain APA as a potential therapeutic target for the treatment of hypertension, which has led to the development of potent orally active APA inhibitors, such as RB150.	firibastat	176-181	glutamyl aminopeptidase	Rattus norvegicus	152-155
24697296-8	2014	RB150 administered orally in hypertensive DOCA (deoxycorticosteroneacetate)-salt rats or SHRs (spontaneously hypertensive rats) crosses the intestinal, hepatic and blood-brain barriers, enters the brain, generates two active molecules of EC33 which inhibit brain APA activity, block the formation of brain AngIII and normalize BP for several hours.	firibastat	0-5	glutamyl aminopeptidase	Rattus norvegicus	263-266
24337978-2	2014	QGC001 (originally named RB150) is a prodrug of the specific and selective APA inhibitor EC33, and as such it is the prototype of a new class of centrally acting antihypertensive agents.	firibastat	25-30	glutamyl aminopeptidase	Homo sapiens	75-78
22710644-6	2012	Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain.	firibastat	23-28	glutamyl aminopeptidase	Rattus norvegicus	90-106
22710644-6	2012	Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain.	firibastat	162-167	glutamyl aminopeptidase	Rattus norvegicus	90-106
22710644-10	2012	Concomitant oral administration of RB150 with a systemic renin-angiotensin system blocker, enalapril, potentiated the RB150-induced blood pressure decrease achieved in <2 hours.	firibastat	35-40	renin	Rattus norvegicus	57-62
22710644-10	2012	Concomitant oral administration of RB150 with a systemic renin-angiotensin system blocker, enalapril, potentiated the RB150-induced blood pressure decrease achieved in <2 hours.	firibastat	118-123	renin	Rattus norvegicus	57-62
22710644-11	2012	Thus, RB150 may be the prototype of a new class of centrally active antihypertensive agents that might be used in combination with classic systemic renin-angiotensin system blockers to improve blood pressure control.	firibastat	6-11	renin	Rattus norvegicus	148-153
21763394-12	2011	This has led to the development of potent orally active APA inhibitors, such as RB150--the prototype of a new class of centrally acting antihypertensive agents.	firibastat	80-85	glutamyl aminopeptidase	Homo sapiens	56-59
18175217-5	2008	This led to the development of potent, systematically active APA inhibitors, such as RB150, as a prototype of a new class of centrally acting antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	85-90	glutamyl aminopeptidase	Homo sapiens	61-64
15748538-5	2005	This justifies the development of potent systemically active APA inhibitors, such as RB150, as prototypes of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	85-90	glutamyl aminopeptidase	Homo sapiens	61-64
18194430-5	2008	This justifies the development of potent systemically active APA inhibitors, such as RB150, as prototypes of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	85-90	glutamyl aminopeptidase	Rattus norvegicus	61-64
15136730-9	2004	in conscious DOCA-salt rats inhibited brain APA activity and markedly reduced blood pressure for up to 24 h. These results demonstrate the crucial role of brain APA as a candidate target for the treatment of hypertension and suggest that RB150, a potent systemically active APA inhibitor, could be the prototype of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	238-243	glutamyl aminopeptidase	Rattus norvegicus	44-47
15136730-9	2004	in conscious DOCA-salt rats inhibited brain APA activity and markedly reduced blood pressure for up to 24 h. These results demonstrate the crucial role of brain APA as a candidate target for the treatment of hypertension and suggest that RB150, a potent systemically active APA inhibitor, could be the prototype of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	238-243	glutamyl aminopeptidase	Rattus norvegicus	161-164
15136730-5	2004	We developed RB150, a prodrug of the specific and selective APA inhibitor, EC33.	firibastat	13-18	glutamyl aminopeptidase	Rattus norvegicus	60-63
15136730-9	2004	in conscious DOCA-salt rats inhibited brain APA activity and markedly reduced blood pressure for up to 24 h. These results demonstrate the crucial role of brain APA as a candidate target for the treatment of hypertension and suggest that RB150, a potent systemically active APA inhibitor, could be the prototype of a new class of antihypertensive agents for the treatment of certain forms of hypertension.	firibastat	238-243	glutamyl aminopeptidase	Rattus norvegicus	161-164
35163378-9	2022	Firibastat is an antihypertensive drug that affects the brain renin angiotensin system by inhibiting aminopeptidase A.	firibastat	0-10	renin	Homo sapiens	62-67
34950965-6	2021	This review introduces firibastat as a new therapeutic class of treatment for hypertension focused on the renin angiotensin system in the brain.	firibastat	23-33	renin	Homo sapiens	106-111
35091008-1	2022	BACKGROUND: Blockade of brain renin-angiotensin system (RAS) overactivity by firibastat, the first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its effectiveness in improving cardiac function after myocardial infarction (MI).	firibastat	77-87	glutamyl aminopeptidase	Mus musculus	116-132
35091008-1	2022	BACKGROUND: Blockade of brain renin-angiotensin system (RAS) overactivity by firibastat, the first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its effectiveness in improving cardiac function after myocardial infarction (MI).	firibastat	77-87	glutamyl aminopeptidase	Mus musculus	134-137
35163378-9	2022	Firibastat is an antihypertensive drug that affects the brain renin angiotensin system by inhibiting aminopeptidase A.	firibastat	0-10	glutamyl aminopeptidase	Homo sapiens	101-117
34020248-7	2021	Interestingly, the chronic administration of a combination of firibastat with [Enalapril+HCTZ] reduced plasma arginine-vasopressin levels by 62% relative to those measured in DOCA-salt rats receiving bitherapy.	firibastat	62-72	arginine vasopressin	Rattus norvegicus	119-130
33881611-8	2021	We demonstrate that the pharmacological blockade of APA with its selective inhibitor RB150 restores the density of mature spines and significantly reduced filopodia-like processes in hippocampal organotypic slices cultures virally transduced with the Swedish mutated Abeta-precursor protein (betaAPP).	firibastat	85-90	glutamyl aminopeptidase	Homo sapiens	52-55
33881611-8	2021	We demonstrate that the pharmacological blockade of APA with its selective inhibitor RB150 restores the density of mature spines and significantly reduced filopodia-like processes in hippocampal organotypic slices cultures virally transduced with the Swedish mutated Abeta-precursor protein (betaAPP).	firibastat	85-90	amyloid beta (A4) precursor protein	Mus musculus	292-299
34020248-0	2021	Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats.	firibastat	11-21	arginine vasopressin	Rattus norvegicus	98-109
34020248-2	2021	Oral administration of firibastat, an APA inhibitor prodrug, in hypertensive rats, inhibits brain APA activity, blocks brain angiotensin III formation and decreases BP.	firibastat	23-33	glutamyl aminopeptidase	Rattus norvegicus	38-41
34020248-2	2021	Oral administration of firibastat, an APA inhibitor prodrug, in hypertensive rats, inhibits brain APA activity, blocks brain angiotensin III formation and decreases BP.	firibastat	23-33	glutamyl aminopeptidase	Rattus norvegicus	98-101
34020248-3	2021	In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers.	firibastat	44-54	arginine vasopressin	Rattus norvegicus	271-282
34020248-8	2021	Our data show that tritherapy with firibastat, enalapril and HCTZ improves BP control and arginine-vasopressin release in an experimental salt-dependent model of hypertension, paving the way for the development of new treatments for patients with currently difficult-to-treat or resistant hypertension.	firibastat	35-45	arginine vasopressin	Homo sapiens	99-110
34020248-3	2021	In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers.	firibastat	44-54	renin	Rattus norvegicus	307-312
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	arginine vasopressin	Rattus norvegicus	66-77
33994025-4	2021	Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension.	firibastat	0-10	carboxypeptidase Q	Homo sapiens	26-40
33683322-0	2021	Brain ACE2 Activation Following Brain Aminopeptidase A Blockade by Firibastat in Salt-dependent Hypertension.	firibastat	67-77	angiotensin I converting enzyme 2	Rattus norvegicus	6-10
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	glutamyl aminopeptidase	Rattus norvegicus	107-110
33683322-0	2021	Brain ACE2 Activation Following Brain Aminopeptidase A Blockade by Firibastat in Salt-dependent Hypertension.	firibastat	67-77	glutamyl aminopeptidase	Rattus norvegicus	38-54
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	angiotensin I converting enzyme 2	Rattus norvegicus	160-164
33683322-3	2021	Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial blood pressure in hypertensive DOCA-salt rats without inducing angiotensin II accumulation.	firibastat	70-75	glutamyl aminopeptidase	Rattus norvegicus	48-51
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	angiotensin I converting enzyme 2	Rattus norvegicus	214-218
33683322-3	2021	Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial blood pressure in hypertensive DOCA-salt rats without inducing angiotensin II accumulation.	firibastat	70-75	angiotensinogen	Rattus norvegicus	15-29
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	254-258
33683322-3	2021	Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial blood pressure in hypertensive DOCA-salt rats without inducing angiotensin II accumulation.	firibastat	76-86	glutamyl aminopeptidase	Rattus norvegicus	48-51
33683322-3	2021	Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial blood pressure in hypertensive DOCA-salt rats without inducing angiotensin II accumulation.	firibastat	76-86	angiotensinogen	Rattus norvegicus	15-29
33683322-5	2021	We found that the intracerebroventricular administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity.	firibastat	60-65	glutamyl aminopeptidase	Rattus norvegicus	126-129
33683322-5	2021	We found that the intracerebroventricular administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity.	firibastat	60-65	angiotensin I converting enzyme 2	Rattus norvegicus	172-176
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	127-132	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	283-287
33683322-5	2021	We found that the intracerebroventricular administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity.	firibastat	66-76	glutamyl aminopeptidase	Rattus norvegicus	126-129
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	133-143	arginine vasopressin	Rattus norvegicus	66-77
33683322-5	2021	We found that the intracerebroventricular administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity.	firibastat	66-76	angiotensin I converting enzyme 2	Rattus norvegicus	172-176
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	133-143	glutamyl aminopeptidase	Rattus norvegicus	107-110
33683322-6	2021	Then, we showed that the decreases in blood pressure and arginine-vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist.	firibastat	133-143	angiotensin I converting enzyme 2	Rattus norvegicus	160-164
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	103-108	angiotensin I converting enzyme 2	Rattus norvegicus	56-60
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	103-108	glutamyl aminopeptidase	Rattus norvegicus	85-88
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	103-108	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	190-194
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	103-108	arginine vasopressin	Rattus norvegicus	309-320
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	109-119	angiotensin I converting enzyme 2	Rattus norvegicus	56-60
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	109-119	glutamyl aminopeptidase	Rattus norvegicus	85-88
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	109-119	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	190-194
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	109-119	arginine vasopressin	Rattus norvegicus	309-320
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	340-345	angiotensin I converting enzyme 2	Rattus norvegicus	56-60
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	340-345	glutamyl aminopeptidase	Rattus norvegicus	85-88
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	340-345	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	190-194
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	346-356	angiotensin I converting enzyme 2	Rattus norvegicus	56-60
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	346-356	glutamyl aminopeptidase	Rattus norvegicus	85-88
33683322-7	2021	Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing angiotensin 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in arginine-vasopressin release induced by RB150/firibastat.	firibastat	346-356	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	190-194
33683322-8	2021	RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.	firibastat	6-16	angiotensin converting enzyme 2	Homo sapiens	205-209
33683322-8	2021	RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.	firibastat	6-16	angiopoietin 1	Homo sapiens	210-217
33683322-8	2021	RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.	firibastat	6-16	MAS1 proto-oncogene like, G protein-coupled receptor	Homo sapiens	218-222
33683322-8	2021	RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.	firibastat	6-16	glutamyl aminopeptidase	Homo sapiens	269-272
32955085-3	2020	The oral administration of RB150 renamed firibastat by WHO, an APA inhibitor prodrug, targeting only the S1 subsite, decreases blood pressure in hypertensive patients from various ethnic origins.	firibastat	27-32	glutamyl aminopeptidase	Homo sapiens	63-66
33520782-0	2021	Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.	firibastat	0-10	glutamyl aminopeptidase	Homo sapiens	37-53
33520782-8	2021	Accumulating evidence from preclinical studies demonstrated that the centrally acting APA inhibitor prodrugs (firibastat and NI956) are very safe and effective at reducing blood pressure in various hypertensive animal models.	firibastat	110-120	glutamyl aminopeptidase	Homo sapiens	86-89
32955085-3	2020	The oral administration of RB150 renamed firibastat by WHO, an APA inhibitor prodrug, targeting only the S1 subsite, decreases blood pressure in hypertensive patients from various ethnic origins.	firibastat	41-51	glutamyl aminopeptidase	Homo sapiens	63-66
32389345-11	2020	Chronic treatment with oral firibastat (4 or 8 weeks after MI) has been shown to normalize brain APA activity in mice.	firibastat	28-38	glutamyl aminopeptidase	Mus musculus	97-100
31786978-5	2020	This has led to development of RB150, an orally active prodrug of the specific and selective APA inhibitor, EC33.	firibastat	31-36	glutamyl aminopeptidase	Rattus norvegicus	93-96
31786978-6	2020	Orally administered RB150 crosses the gastrointestinal and blood-brain barriers, enters the brain where it generates 2 active molecules of EC33 that block brain APA activity.	firibastat	20-25	glutamyl aminopeptidase	Rattus norvegicus	161-164